CellCentric, a clinical-stage biotechnology startup developing an oral treatment for multiple myeloma, has raised £160 million in a Series D financing led by Venrock Healthcare Capital Partners. Proceeds will support the advancement of inobrodib through pivotal clinical development studies, including continued enrollment of the Phase 2 DOMMINO-1 study in the United Kingdom and United States and initiation of the global Phase 3 DOMMINO-2 trial in the second half of 2026.
Developed as a first-in-class p300/CBP inhibitor, inobrodib is designed to treat patients with relapsed or refractory multiple myeloma, including those who have already received multiple prior therapies. Delivered as an oral capsule, the treatment can be administered at home without the need for intensive monitoring. Clinical data has shown activity in heavily pretreated patients, including in combination with pomalidomide and dexamethasone, where response rates were at least twice those of historic alternative therapies.
Funding will also support expansion of inobrodib into additional combination and maintenance treatment settings. Alongside its use with standard therapies, the drug is being explored in combination with bispecific treatments and in maintenance settings, with ongoing clinical development across multiple indications.
We are thrilled to have the support of top-tier investors who believe in inobrodib’s potential to address a critical need in multiple myeloma, notably after bispecific T cell engager or anti-BCMA therapies. This is a significant and growing unmet need. Inobrodib is a new modality and a potential fresh option for patients that is orally administered. In combination with pomalidomide and dexamethasone as InoPd, we have demonstrated deep responses in heavily pretreated relapsed or refractory multiple myeloma patients. Fueled by this funding, we are well positioned to complete registration enabling studies for the all-oral triplet and advance our progress toward delivering a transformative treatment.
What stands out with inobrodib is the consistency of clinical activity alongside a manageable safety profile in a heavily pretreated population. An oral drug with a novel, additive approach could play an important role in later-line therapy, as well as across the treatment landscape in multiple myeloma. We are excited to support its advancement into pivotal studies.
